Search PubMed⌕ Search

Biomedical subjects

H Munitz

Publications and source records attributed to H Munitz.

At least 19 recordsLinked to original sources
PubMed1992

Electroconvulsive therapy for persistent neuroleptic-induced akathisia and parkinsonism: a case report.

Neuroleptic-induced akathisia (NIA) and parkinsonism (NIP) continued for 3 months, despite two courses of anticholinergic treatments, a shift to low-potent neuroleptic (NL) and a NL-free period. The two adverse effects responded dramatically to electroconvulsive therapy (ECT) to reemerge 3 months after termination of ECT. The case supports the idea that ECT is effective for both NIA and NIP even when they are resistant.

Adult↗
PubMed1992

Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients.

The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.

Administration, Oral↗
PubMed1991

Event-related potentials in drug-naive schizophrenic patients.

Decreased amplitudes of late components of event-related potentials (ERPs) in schizophrenia were ascribed to either psychotic features or to neuroleptic treatment of the patients. To rule out the drug effect, ERPs to stroboscopic stimuli were recorded in drug-naive schizophrenics and control subjects during no-task and simple-task sessions. Patients had significantly lower amplitudes of the late ERP components during both sessions, thus confirming similar results with treated schizophrenics. On the other hand, drug-naive patients did not differ from controls in the task-related relative facilitation of late ERP components. These results differ from findings of minimal ERP facilitation to task in treated schizophrenics. This discrepancy is discussed in the context of the effects of neuroleptic treatment and task demands on ERPs.

Adult↗
PubMed1991

TRH stimulation test in obsessive-compulsive patients.

Serum thyroid stimulating hormone (TSH), prolactin (PRL), and growth hormone (GH) levels were measured before and after stimulation with 200 micrograms of thyrotropin releasing hormone (TRH) in 10 patients with obsessive-compulsive disorder (OCD) and in 10 control subjects. There were significantly more blunted TSH responses among OCD patients than control subjects. PRL and GH responses to TRH challenge did not differ between OCD patients and controls. These results may indicate dysregulation of the hypothalamic-pituitary-thyroid axis in OCD.

Adult↗
PubMed1990

Unilateral neuroleptic-induced akathisia.

Four cases of acute unilateral neuroleptic-induced akathisia (NIA) are presented. The NIA included unilateral subjective symptoms as well as unilateral observable motor signs, and they responded favorably to either anticholinergic medication or propranolol (PPN) up to 100 mg/day. These descriptions suggest that acute NIA might sometimes be presented in an atypical hemipresentation that is highly liable to be misdiagnosed.

Acute Disease↗
PubMed1990

Immunoreactive beta-endorphin, cortisol, and growth hormone plasma levels in obsessive-compulsive disorder.

Basal morning plasma levels of immunoreactive-beta-endorphin (ir-beta-EP), cortisol, and growth hormone (GH) were assessed in 13 obsessive-compulsive disorder (OCD) patients in comparison to 20 healthy controls. All subjects were drug free for at least 1 year. The mean plasma level of ir-beta-EP was significantly lower (36%) in the OCD patients when compared with the control subjects. The decrease in ir-beta-EP was not accompanied by alteration in cortisol and GH plasma levels.

Adolescent↗
PubMed1990

Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder.

Trazodone (TZ) was administered to nine patients suffering from obsessive-compulsive disorder (OCD), who failed to respond to either clomipramine (CMI) or to CMI plus lithium carbonate. The group, as a whole, showed significant but mild improvement. Three patients responded very favorably to TZ. In these three responders, efficacy was substantiated by the return of the original obsessive-compulsive (OC) symptoms following TZ withdrawal and their amelioration after its readministration. Interestingly, the aggravation of OCD symptomatology that has been associated with a specific TZ metabolite was not observed. This study is consistent with previous reports of the anti-OC efficacy of TZ and suggests the involvement of complex serotonergic mechanisms in the pathophysiology of this disorder.

Adult↗
PubMed1990

Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.

Development of neuroleptic malignant syndrome (NMS) following discontinuation of high-dose and high-potency neuroleptic agents is described. This case, although rare and atypical, should alert clinicians to consider the possibility of NMS as a complication of abrupt neuroleptic drug withdrawal. It is suggested that dopaminergic imbalance, as opposed to excessive dopaminergic blockade, may also play a role in the precipitation of NMS.

Adolescent↗
PubMed1989

Pseudocholinesterase in obsessive-compulsive patients.

Levels of pseudocholinesterase (PsChe) were measured in 20 patients with obsessive-compulsive disorder (OCD) and 20 healthy volunteers. The OCD group had significantly higher PsChe serum activity than in their sex- and age-matched control group. Patients' scores on the Hamilton Rating Scale for Anxiety (HRS-A) and the Beck Depression Inventory (BDI) were not correlated with their PsChe levels. The results provide additional support for the observation of higher PsChe levels among anxiety-related psychiatric conditions. However, the relationships among anxiety, depression, and PsChe appear to be complex. The nature and implications of elevated PsChe levels are still unknown.

Adult↗